Pacific Biosciences of California, Inc. provided revenue guidance for the full year 2022. As a result of macroeconomic factors discussed above, the company now expected 2022 revenue to be in the range of $138 million to $145 million.
Pacific Biosciences of California, Inc.
Equities
PACB
US69404D1081
Advanced Medical Equipment & Technology
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.755 USD | -6.40% | -4.05% | -81.91% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-81.91% | 511M | |
+6.58% | 219B | |
+10.34% | 192B | |
+18.61% | 142B | |
+29.85% | 111B | |
+2.09% | 65.32B | |
+14.83% | 52.45B | |
+3.01% | 49.8B | |
+4.88% | 43.43B | |
+1.23% | 35.95B |
- Stock Market
- Equities
- PACB Stock
- News Pacific Biosciences of California, Inc.
- Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Full Year 2022